Emergent BioSolutions | EBS - 負債





負債 変化する 日付
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Akebia Therapeutics USD 46.51M 7.82M 2025-03
ALKERMES USD 71.6M 1.08M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amarin USD 0 0 2025-03
ANI Pharmaceuticals USD 617.04M 3.28M 2025-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Coherus Biosciences USD 294.92M 1.25M 2025-03
Emergent BioSolutions USD 903.2M 495.2M 2023-06
Exact Sciences USD 2.34B 15.24M 2025-09
Exelixis USD 176.46M 3.38M 2025-09
Glaxosmithkline GBP 17.75B 396M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Lexicon Pharmaceuticals USD 99.26M 493K 2023-09
Lonza CHF 4.71B 915M 2024-12
Merck USD 41.37B 5.97B 2025-09
Moderna USD 734M 7M 2025-09
Myriad Genetics USD 59.3M 19.7M 2025-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Pacira USD 372.19M 4.53M 2025-12
Pfizer USD 60.85B 78M 2025-09
PTC Therapeutics USD 286.32M 306K 2025-09
Sanofi EUR 21.76B 530M 2025-09
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12
Xoma USD 120.79M 3.27M 2024-06